Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 29

1.

Polypoid endometriosis mimicking invasive cancer in an obese, postmenopausal tamoxifen user.

Jaegle WT, Barnett JC, Stralka BR, Chappell NP.

Gynecol Oncol Rep. 2017 Oct 31;22:105-107. doi: 10.1016/j.gore.2017.10.004. eCollection 2017 Nov.

2.

Are different methotrexate regimens as first line therapy for low risk gestational trophoblastic neoplasia more cost effective than the dactinomycin regimen used in GOG 0174?

Miller CR, Chappell NP, Sledge C, Leath CA 3rd, Phippen NT, Havrilesky LJ, Barnett JC.

Gynecol Oncol. 2017 Jan;144(1):125-129. doi: 10.1016/j.ygyno.2016.10.038. Epub 2016 Nov 3.

3.

Is FDA-Approved Bevacizumab Cost-Effective When Included in the Treatment of Platinum-Resistant Recurrent Ovarian Cancer?

Chappell NP, Miller CR, Fielden AD, Barnett JC.

J Oncol Pract. 2016 Jul;12(7):e775-83. doi: 10.1200/JOP.2015.010470. Epub 2016 May 31.

PMID:
27246689
4.

Does Routine Posttreatment PET/CT Add Value to the Care of Women With Locally Advanced Cervical Cancer?

Phippen NT, Havrilesky LJ, Barnett JC, Hamilton CA, Stany MP, Lowery WJ.

Int J Gynecol Cancer. 2016 Jun;26(5):944-50. doi: 10.1097/IGC.0000000000000705.

PMID:
27051057
5.

Laparoscopic staging of ovarian immature teratomas: a report on three cases.

Brown KL, Barnett JC, Leath CA 3rd.

Mil Med. 2015 Mar;180(3):e365-8. doi: 10.7205/MILMED-D-14-00288.

PMID:
25735031
6.

Costs, effectiveness, and workload impact of management strategies for women with an adnexal mass.

Havrilesky LJ, Dinan M, Sfakianos GP, Curtis LH, Barnett JC, Van Gorp T, Myers ER.

J Natl Cancer Inst. 2014 Dec 16;107(1):322. doi: 10.1093/jnci/dju322. Print 2015 Jan.

PMID:
25515232
7.

The cost-effectiveness of selective lymphadenectomy based on a preoperative prediction model in patients with endometrial cancer: insights from the US and Korean healthcare systems.

Lee JY, Cohn DE, Kim Y, Lee TJ, Barnett JC, Kim JW, Jeon YW, Kim K, Park SM, Kang S.

Gynecol Oncol. 2014 Dec;135(3):518-24. doi: 10.1016/j.ygyno.2014.09.020. Epub 2014 Oct 29.

PMID:
25450150
8.

A cost-utility analysis of NRG Oncology/Gynecologic Oncology Group Protocol 218: incorporating prospectively collected quality-of-life scores in an economic model of treatment of ovarian cancer.

Cohn DE, Barnett JC, Wenzel L, Monk BJ, Burger RA, Straughn JM Jr, Myers ER, Havrilesky LJ.

Gynecol Oncol. 2015 Feb;136(2):293-9. doi: 10.1016/j.ygyno.2014.10.020. Epub 2014 Oct 23.

9.

Bevacizumab in recurrent, persistent, or advanced stage carcinoma of the cervix: is it cost-effective?

Phippen NT, Leath CA 3rd, Havrilesky LJ, Barnett JC.

Gynecol Oncol. 2015 Jan;136(1):43-7. doi: 10.1016/j.ygyno.2014.11.003. Epub 2014 Nov 9.

10.

Primary invasive breast carcinoma arising in mammary-like glands of the vulva managed with excision and sentinel lymph node biopsy.

Butler B, Leath CA 3rd, Barnett JC.

Gynecol Oncol Case Rep. 2013 Sep 12;7:7-9. doi: 10.1016/j.gynor.2013.09.001. eCollection 2014 Jan.

11.

Trends in hospital volume and patterns of referral for women with gynecologic cancers: adherence to treatment guidelines for ovarian cancer as a measure of quality care.

Barnett JC, Phippen NT, Leath CA 3rd.

Obstet Gynecol. 2013 Oct;122(4):905-6. doi: 10.1097/AOG.0b013e3182a79fd0. No abstract available.

PMID:
24084554
12.

Cost effectiveness of alternative strategies for incorporating bevacizumab into the primary treatment of ovarian cancer.

Barnett JC, Alvarez Secord A, Cohn DE, Leath CA 3rd, Myers ER, Havrilesky LJ.

Cancer. 2013 Oct 15;119(20):3653-61. doi: 10.1002/cncr.28283. Epub 2013 Aug 6.

13.

Surgical outcomes and national comprehensive cancer network compliance in advanced ovarian cancer surgery in a low volume military treatment facility.

Phippen NT, Barnett JC, Lowery WJ, Miller CR, Leath CA 3rd.

Gynecol Oncol. 2013 Oct;131(1):158-62. doi: 10.1016/j.ygyno.2013.07.001. Epub 2013 Jul 16.

PMID:
23872110
14.

Cost-effectiveness of early palliative care intervention in recurrent platinum-resistant ovarian cancer.

Lowery WJ, Lowery AW, Barnett JC, Lopez-Acevedo M, Lee PS, Secord AA, Havrilesky L.

Gynecol Oncol. 2013 Sep;130(3):426-30. doi: 10.1016/j.ygyno.2013.06.011. Epub 2013 Jun 14.

PMID:
23769759
15.

Are supportive care-based treatment strategies preferable to standard chemotherapy in recurrent cervical cancer?

Phippen NT, Leath CA 3rd, Miller CR, Lowery WJ, Havrilesky LJ, Barnett JC.

Gynecol Oncol. 2013 Aug;130(2):317-22. doi: 10.1016/j.ygyno.2013.05.019. Epub 2013 May 23.

PMID:
23707667
16.

Re: "The utilization of palliative care in gynecologic oncology patients near the end of life".

Barnett JC, Leath CA 4th.

Gynecol Oncol. 2012 Dec;127(3):678-9; author reply 679. doi: 10.1016/j.ygyno.2012.08.009. Epub 2012 Aug 16. No abstract available.

PMID:
22902519
17.

Cost effectiveness of concurrent gemcitabine and cisplatin with radiation followed by adjuvant gemcitabine and cisplatin in patients with stages IIB to IVA carcinoma of the cervix.

Phippen NT, Leath CA 3rd, Chino JP, Jewell EL, Havrilesky LJ, Barnett JC.

Gynecol Oncol. 2012 Nov;127(2):267-72. doi: 10.1016/j.ygyno.2012.08.002. Epub 2012 Aug 11.

PMID:
22892361
18.

Economic impact of paclitaxel shortage in patients with newly diagnosed ovarian cancer.

Havrilesky LJ, Garfield CF, Barnett JC, Cohn DE.

Gynecol Oncol. 2012 Jun;125(3):631-4. doi: 10.1016/j.ygyno.2012.03.028. Epub 2012 Mar 23.

PMID:
22446408
19.

Cost analysis of abdominal, laparoscopic, and robotic-assisted myomectomies.

Behera MA, Likes CE 3rd, Judd JP, Barnett JC, Havrilesky LJ, Wu JM.

J Minim Invasive Gynecol. 2012 Jan-Feb;19(1):52-7. doi: 10.1016/j.jmig.2011.09.007. Epub 2011 Nov 18.

PMID:
22100443
20.

Incidence of subsequent abnormal cytology in cervical cancer patients completing five-years of post treatment surveillance without evidence of recurrence.

Orr JM, Barnett JC, Leath CA 3rd.

Gynecol Oncol. 2011 Sep;122(3):501-4. doi: 10.1016/j.ygyno.2011.06.003. Epub 2011 Jun 28.

PMID:
21714992

Supplemental Content

Loading ...
Support Center